Roche has announced that its latest cobas 6800/8800 systems 2.0 have obtained CE certification. This revision significantly boosts operational efficiency in lab settings by optimizing resources, minimizing downtime, consolidating testing options, and increasing capacity. These advancements aim to deliver a more seamless diagnostic experience for medical professionals and their patients.
“This enhancement represents another pivotal development for Roche,” stated Matt Sause, CEO of Roche Diagnostics. “Building on our reputation for pioneering automated molecular testing solutions, it signifies another significant advancement in refining PCR technology, elevating both throughput and the adaptability required by laboratories to effectively serve healthcare providers and patients.”
The newly updated cobas systems are compatible with the majority of the existing test menu, including the new and innovative Temperature-Activated Generation of Signal (TAGS) technology. This new system allows for the detection of up to 15 targets simultaneously from a single patient sample using the cobas 5800, 6800, and 8800 high-capacity molecular diagnostic analysers.
The cobas 6800/8800 systems are tailored to meet the demands faced by laboratories with moderate to high testing volumes. By integrating the latest innovations designed to revolutionize the testing process, these systems provide intelligent workflows, unmatched throughput, reliable performance, enduring dependability, and exceptional flexibility.
With this update, the cobas line of solutions delivers a cohesive user experience, embedding significant innovations seen in the latest member, the cobas 5800 system.
An FDA 510(k) clearance in the US is expected following a submission scheduled for 2025.
Established in 1896 in Basel, Switzerland, as one of the initial industrial manufacturers of branded pharmaceutical products, Roche has evolved to become the world’s preeminent biotechnology company and a leader in in-vitro diagnostics globally.